In order to examine the clinical features of severe acute exacerbation in chronic hepatitis B virus (HBV) infection, 297 hepatitis B surface antigen (HBsAg) carriers were followed for 35+22 months (mean+s.D.) in Tohoku University Hospital from 1976 to 1987. Of these, 10 experienced severe acute exacerbation with hepatic decompensation. All of these patients had intense subjective symptoms related to the hepatitis. They were all icteric and 8 had ascites. Three developed to fulminant hepatic failure, eventually died. Histology after the exacerbation showed severe hepatic damage such as massive hepatic necrosis and bridging hepatic necrosis in a half of them. Six cases were suspected to result from spontaneous reactivation and 2 from drug-induced reactivation of chronic HBV infection, and the other 2 from superinfection with non-A, non-B hepatitis agent (s). These results suggest that the reactivation of chronic HBV infection is an important factor of severe acute exacerbations in chronic HBV infection in Japan.
Patients with chronic type B hepatitis positive for hepatitis B e antigen (HBeAg) are considered to experience frequent acute exacerbations (Perrilo et al. 1984 ; Liaw et al. 1987 ). However, the exacerbations occasionally occur in hepatitis B surface antigen (HBsAg) carriers negative for HBeAg (Liaw et al. 1987) . Such exacerbations are considered to be induced by the spontaneous reactivation of chronic hepatitis B virus (HBV) infection and superinfections with hepatitis A virus (HAY) (Zachoval et al. 1983 ; Davis et al. 1984b ), non-A, non-B (NANB) hepatitis agent (s) (Papaevangelou et al. 1984 ) and hepatitis delta virus (HDV) (Smedile et al. 1982 ; Govindarajan et al. 1984) . Although patients suffer elevation of hepatic enzymes, the clinical symptoms are mild, or, like the physical findings of chronic liver diseases, often absent (Hoofnagle and Alter 1984) . In rare cases, severe exacerbations with hepatic decompensation have also been reported in such patients (Sheen et al. 1985; Tassopoulos et al. 1986 ). During the past 10 years, of 297 HBsAg carriers we have examined, there have been 10 cases with severe acute exacerbation.
In this study, the clinical features of severe acute exacerbation in HBsAg carriers have been examined with respect to their biochemical and virological aspects, and their probable etiologies have been discussed.
MATERIALS and METHODS

Patients
Two hundred and ninety-seven chronic carriers of HBsAg (216 males and 81 females ; mean age, 32.7±14.0 years) were followed for up to 8 years (35+22 months, mean+s.D.) in Tohoku University Hospital from 1976 to 1987. Of these, 170 had chronic liver diseases and 127 were asymptomatic carriers. HBeAg was positive in 169 and negative in 128 at beginning of the observation. Physical examination and liver function test were carried out every 1 to 3 months. Severe acute exacerbation in chronic HBV infection was defined by the following features : 1. Abrupt elevation of alanine aminotransferase (ALT) levels to higher than 300IU/liter.
2. Subjective symptoms related to hepatitis such as anorexia, nausea, malaise and upper abdominal pain. 3. Physical signs of hepatic decompensation such as jaundice, ascites and encephalopathy. 4. Decrease of prothrombin activity to below 40%. Acute HDV superinfection was diagnosed by seroconversion to antibody against HDV (anti-HDV) in acute or convalescent phase. Reactivation of chronic HBV infection was diagnosed by the presence of markers of active HBV replication such as HBeAg, HBV DNA and immunoglobulin M (IgM) class antibody against hepatitis B core antigen (IgM anti-HBc) (Tassopoulos et al. 1986 ), and HBcAg in liver ). The diagnosis of acute NANB hepatitis superimposed on chronic HBV infection was made by exclusion of HAV, Epstein-Barr virus (EBV), cytomegalovirus (CMV), drug-induced or alcoholic liver disease, and by the absence of active HBV replication (Tassopopulos et al. 1986 ). Liver tissues were obtained from patients with abnormal liver function test by biopsy under laparoscopy or by autopsy, with each patient's or bereaved family's informed consent. Sections were stained by conventional methods. Hepatic histology was interpreted according to the standard criteria (Review by an International Group 1977). Bridging hepatic necrosis was defined as a lesion showing hepatic necrosis and collapse that bridged adjacent portal or central veins or both (Boyer and Klatskin 1970) . Massive hepatic necrosis meant confluent necrosis with extensively involved several adjacent lobules or complex lobules in a substantial part of the liver (Bianchi et al. 1979 ).
Serological testing
HBV-related markers were tested as follows : HBsAg and antibody against HBsAg (anti-HBs) were examined by reversed passive hemagglutination and passive hemagglutination (Antihebcell and Hebsgencell, The Green Cross Corp., Osaka), respectively. HBeAg, antibody against HBeAg (anti-HBe), total anti-HBc, IgM anti-HBc, IgM anti-HAV and total anti-HDV were examined by commercial radioimmunoassay or enzyme-linked immunosorbent assay kits (Abbott Laboratories, North Chicago, IL, USA). Antibody against capsular antigen of EBV and antibody against CMV were tested by direct immunofluorescence and complement fixation, respectively. Serum HBV DNA measurement Serum HBV DNA was detected by the spot hybridization technique using a 32P-labeled cloned HBV DNA probe according to the method described in a previous paper ).
Detection of HBcAg in liver
As described previously (Akiba et al. 1987 ), HBcAg in liver was stained by the avidin-biotin-peroxidase complex method.
RESULTS
Ten of the 297 HBsAg carriers experienced severe acute exacerbations with abrupt elevation of ALT levels to higher than 300 IU/liter during the observation period. The clinical features of these patients are summarized in Table 1 . They were all male and the mean age was 38.8+ 11.5 years. The mean peak values of aspartate aminotransferase (AST) and ALT levels were 1,542± 1,116 IU/liter (range, 502-4,200 IU/liter) and 1,655± 1,363 IU/liter (range, 513-5,050 IU/liter), respectively. They were all icteric and the mean peak value of total bilirubin was 16.1+9.9 mg/100 ml (range, 5.1-33.6 mg/100 ml), and prothrombin activities decreased to below 40%. Seven patients complained of anorexia, 5 of malaise and 5 of epigastralgia. Three had a mild fever below 38°C. Ascites were observed in 8 patients. Hepatic encephalopathy developed in 3, who eventually died. Histological examinations of liver were also performed ( Table 2) : Before exacer- Virological findings during severe acute exacerbation in 10 HBsAg carriers bation, 2 were diagnosed as having chronic active hepatitis and 3 as having liver cirrhosis. After exacerbation, 3 were diagnosed as having massive hepatic necrosis (Fig, la) , 2 as having chronic active hepatitis with bridging hepatic necrosis and 1 as having liver cirrhosis. Virological findings of the 10 cases with severe acute exacerbation are described in Table 3 , with their probable etiologies. None of these patients, except 2 (Cases No. 1 and 2) whose sera were not available for serological testings, were found to be superimposed with HAV or HDV. According to the serological criteria described in Materials and Methods, 5 patients (Cases No. 3, 6-9) belonged to the spontaneous reactivation of chronic HBV infection group. The severe exacerbation in the Case No. 2 might be induced by spontaneous reactivation of chronic HBV infection in view of positive result for HBcAg in the liver (Fig. lb) , although the true etiology was unknown because of unavailability of the serum. In two patients (Cases No. l and 5), severe exacerbation was likely to result from drug-induced reactivation of chronic HBV infection ; Case No. l had been receiving chemotherapy for malignant lymphoma for 2 months. Eleven days after stopping the drugs, he experienced an abrupt elevation of ALT level, and developed to fulminant hepatic failure. Case No. 5 experienced also an abrupt elevation of ALT level with hepatic decompensation during withdrawal of prednisolone administered for nephrotic syndrome. In these patients, elevation of serum HBV DNA levels was found at the exacerbation. One patient (Case No. 10) contracted acute NANB hepatitis 10 days after transfusion of anti-hemophiliacs IX. In the Case No. 4 positive for HBeAg but negative for HBV DNA in serum, it is difficult to verify the true etiology of the exacerbation. However, it might be attributed to NANB hepatitis, because he had received blood transfusions 70 days before the episodes.
DISCUSSION
The majority of patients with chronic type B hepatitis, even during periods of elevation of hepatic enzyme levels, have mild or no subjective symptoms, and physical findings are often absent (Hoofnagle and Alter 1984) . In the present study, however, all patients with severe exacerbation had subjective symptoms that were often intense. They were all icteric to a high degree. These clinical features resemble those of acute type B hepatitis (Bortolotti et al. 1986 ). The histological findings of liver showed severe hepatic injuries such as massive hepatic necrosis and bridging hepatic necrosis, which suggest that hepatocytes were affected by drastic immune responses (Sheen et al. 1985) . It has been also reported that bridging hepatic necrosis is a predictive indicator of the progress of chronic active hepatitis to cirrhosis (Cooksley et al. 1986 ). In view of these facts, it may be suggested that repeated severe exacerbations facilitate the progress of chronic liver disease to cirrhosis, as shown in the patient (Case No. 7) with cirrhosis who had shown chronic active hepatitis before the exacerbation.
One (Case No. 1) of the three patients who developed fulminant hepatic failure was an HBsAg carrier with malignant lymphoma receiving chemotherapy. The histological examination revealed massive hepatic necrosis. A similar outcome was reported in another study (Thung et al. 1985) . It is considered that chemotherapy--induced immunosupression may be faborable to the spread of HBV infection among hepatocytes, and that a host's cellular immune response to viral antigen may rebound when the therapy is stopped. In some of these patients, it may result in massive hepatic necrosis (Galbraith et al. 1975 ; Wand 1975 ; Hoofnagle et al. 1982 ). In the same way, a pronounced rebound of immune response to HBV replication with rapid tapering or abrupt discontinuance of immunosupressants such as steroids may precipitate hepatic decompensation in HBsAg-positive patients with chronic liver diseases like our patient (Case No. 5) (Schullard et al. 1981; Nair et al. 1986 ).
Two patients probably had NANB hepatitis superimposed on chronic HBV infection. Although a large number of patients with acute NANB hepatitis appear to be asymptomatic and anicteric (Dienstag 1983) , those with advanced liver diseases may have a tendency to hepatic decompensation by superinfection of NANB hepatitis agent (s) like our cases (Papaevangelou et al. 1984) . Our failure to detect anti-HDV in the sera of patients experiencing severe exacerbation suggested that HDV infection may not play an important role in severe acute exacerbation in chronic carriers of HBsAg in Japan. Our findings are compatible with reports from Greece (Tassopoulos et al. 1986 ), Maryland in the United States (Davis et al. 1984a ) and Taiwan (Sheen et al. 1985) , while inconsistent with those from Italy (Smedile et al. 1982) and California in the United States (Govindarajan et al. 1984) . The difference may be attributed to the lower prevalence of HDV infection in the former areas (and in Japan) than in the latter (Rizzetto et al. 1980 ). Six patients (2 positive and 4 negative for HBeAg) were suspected to be caused by spontaneous reactivation of chronic HBV infection because of the presence of serological or histological markers of active viral replication. Taking these facts into consideration, it is likely that spontaneous reactivation is an important factor of severe acute exacerbation in HBsAg carriers, irrespective of the HBeAg/anti-HBe immune status (Papaevangelou et al. 1984; Perrilo et al. 1984; Tassopoulos et al. 1986 ).
